Juvianee I Estrada-Veras
EducationDr. Estrada-Veras is a Doctor of Medicine, Magna Cum Laude, from the Instituto Tecnologico de Santo Domingo in the Dominican Republic (2003). He completed residency training in pediatrics at the State University of New York (SUNY) Health Science Center and University Hospital in Brooklyn, NY in 2009. Following this, he joined the NIH Medical Genetics and Genomic Medicine training program at the National Human Genome Research Institute (NHGRI) where he completed residency training in clinical genetics and fellowship training in medical biochemical genetics in 2012. He is specialty board certified in general pediatrics by the American Board of Pediatrics, as well as Clinical Genetics and Medical Biochemical Genetics by the American board of Medical Genetics and Genomics.
BiographyDr. Estrada-Veras is a Doctor of Medicine, Magna Cum Laude, from the Instituto Tecnologico de Santo Domingo in the Dominican Republic (2003). He completed residency training in pediatrics at the State University of New York (SUNY) Health Science Center and University Hospital in Brooklyn, NY in 2009. Following this, he joined the NIH Medical Genetics and Genomic Medicine training program at the National Human Genome Research Institute (NHGRI) where he completed residency training in clinical genetics and fellowship training in medical biochemical genetics in 2012. He is specialty board certified in general pediatrics by the American Board of Pediatrics, as well as Clinical Genetics and Medical Biochemical Genetics by the American board of Medical Genetics and Genomics. He remained as staff clinician at NHGRI/NIH as principal investigator from 2012 to 2017. Since then, he continues his role at NHGRI/NIH as clinical investigator through NHGRI Office of the Clinical Director. He joined WRNMMC/JPMCC/HJF/USUHS Department of Surgery on March 14th, 2017.
Dr. Estrada-Veras is currently Head Clinical Geneticist for the MCC and MCCRP Clinical Cancer Genetics Program at Walter Reed National Military Medical Center, serving both the clinical cancer genetics and research cancer genetics needs per MCCRP vision and direction. Within this role, he oversees the daily operations of the clinical cancer genetics program at MCC and provides consultations through the general genetics clinical service. Through this position, he is also Head Clinical Geneticist for the MCCRP Cancer Genetics Program across all of MCCRP’s Department of Defense network sites where he supports the clinical cancer geneticist needs and requirements of the MCCRP’s APOLLO (Applied Organizational Learning and Outcomes) translational (clinical/research) program at all sites and Walter Reed for the APOLLO “Genetics Return of Results” program.
In addition, his clinical duties include education in general genetics and in implementation of genetic services. He works closely with medical students from USUHS, residents and fellows from WRNMMC as well as residents and fellows of the NIH Medical Genetics and Genomic Medicine training program and genetic counseling students when they rotate through the clinical cancer genetics clinic or the general genetics clinic. Dr. Estrada-Veras is also working on establishing a precision oncology consult service through MCC and introducing pharmacogenetic testing as clinical testing for patients through MCC.
Dr. Estrada-Veras has received several awards for his outstanding medical care, including the Genome Recognition of Employee Accomplishments and Talents (G.R.E.A.T.) from the NIH-NHGRI. In 2016, he received the Distinguished Alumnus Award from his medical school as recognition of his research efforts for rare diseases at NHGRI/NIH. Most recent, in 2021 he received the Associate Master Clinician Award from Walter Reed NMMC / USUHS – NSAB for his performance in clinical care at WRNMMC.
Publications include clinical peer-reviewed manuscripts in prestigious journals including Blood, Blood Advances, JAMA Open Access, Cancer Discovery, Molecular Genetics and Genomic Medicine, Human Molecular Genetics as well as Human Mutation. He was invited as senior author by the JNCCN—Journal of the National Comprehensive Cancer Network as author of "Survivorship Issues in Adult Patients With Histiocytic Neoplasms" to be included as reference material for the upcoming NCCN guidelines for histiocytic neoplasms.
Representative publications, projects, and/or deployments
USUHS/MCCRP/HJF/Walter Reed NMMC / WRNMMC-2018-0147: Applied Proteogenomics Organizational Learning and Outcomes (APOLLO) Protocol. PI: Craig D. Shriver MD.
USUHS.2020-039-001 Pharmacogenomics in the Military Healthcare System: Comparison of two PGx Platforms," Uniformed Services University of the Health Sciences, Bethesda, MD.
2015 : Globes of Excellence; Erdheim Chester Disease Global Alliance
2015: Genome Recognition of Employee Accomplishments and Talents (G.R.E.A.T.) Awards ; NIH –NHGRI
2016 : Distinguished Alumnus Award in Medicine; Instituto Tecnologico de Santo Domingo
2021 : Associate Master Clinician; Walter Reed NMMC / USUHS – NSAB.
Estrada-Veras JI, Cabrera-Peña GA, Pérez-Estrella de Ferrán C. Medical genetics and genomic medicine in the Dominican Republic: Challenges and opportunities” Mol Genet Genomic Med 4: 243–56, 2016
Estrada-Veras JI, O’Brien KJ, Boyd LC, Dave RH, Durham B, Xi L, Malayeri AA, Chen MY, Gardner PJ, Alvarado-Enriquez JR, Shah N, Abdel-Wahab O, Gochuico BR, Raffeld M, Jaffe ES, Gahl WA, “ The Clinical Spectrum of Erdheim Chester Disease: an Observational Cohort Study” Blood Advances. Volume 1(6):357-366, February 14, 2017
Kevin O’Brien, RN, MS, CRNP; Rahul Dave, MD, PhD; Skand Shekhar, MD; Fady Hannah-Shmouni, MD, FRCPC; Leora E. Comis, MPA, OTR/L5; Beth I. Solomon, MS, CCC-SLP; Marcus Chen, MD; William A. Gahl, MD, PhD; Edmund Fitzgibbon, MD; Bernadette R. Gochuico, MD; and Juvianee I. Estrada-Veras, MD. Survivorship Issues in Adult Patients With Histiocytic Neoplasms. J Natl Compr Canc Netw 2021;19(11):1–8
Goyal G, Heaney ML, Collin M, Cohen Aubart F, Vaglio A, Durham BH, Hershkovitz-Rokah O, Girschikofsky M, Jacobsen ED, Toyama K, Goodman AM, Hendrie P, Cao XX, Estrada-Veras J, Shpilberg O, Abdo A, Kurokawa M, Dagna L, McClain KL, Mazor RD, Picarsic J, Janku F, Go RS, Haroche J, Diamond E. Erdheim-Chester disease: Consensus recommendations for the evaluation, diagnosis, and treatment in the molecular era. Blood. 2020 Mar 18. pii: blood.2019003507. doi: 10.1182/blood.2019003507
Hellwig LD, Turner C, Manolio TA, Haigney M, James CA, Murray B, Szpisjak DF, Muldoon S, Estrada-Veras J, Krokosky A, De Castro MJ. Return of secondary findings in genomic sequencing: Military implications. Mol Genet Genomic Med. 2019 Feb;7(2):e00483. doi: 10.1002/mgg3.483. Epub 2018 Nov 10. Review.
Bai R, Cui H, Devaney JM, Allis KM, Balog AM, Liu X, Schnur RE, Shapiro FL, Brautbar A, Estrada-Veras JI, Hochstetler L, McConkie-Rosell A, McDonald MT, Solomon BD, Hofherr S, Richard G, Suchy SF. Interference of nuclear mitochondrial DNA segments in mitochondrial DNA testing resembles biparental transmission of mitochondrial DNA in humans. Genet Med. 2021 Apr 12. doi: 10.1038/s41436-021-01166-1.
Fady Hannah-Shmounia, Louisa Boyd, Georgios Z. Papadakis, Amit Tirosh, William A Gahl, Juvianee I. Estrada-Veras, Kevin O'Brien. Association of BRAF V600E with Hypothalamic-Pituitary-Adrenal Axis Involvement in Erdheim-Chester Disease. Endocrine and Metabolic Science, Volume 1, Issues 1–2, July 2020, 100051
Robert M Gaeta, John M Childs, Anandita A Datta, Juvianee Estrada Veras, Robert Nee, Christina M Yuan, John S Thurlow. A Case Report Of A Novel Variant Of X-Linked Alport Syndrome. Journal of Nephrology & Renal Therapy AUG 2018 DOI:10.24966/NRT-7313/100017
Schmidt L, Wain KE, Hajek C, Estrada-Veras JI, Guillen Sacoto MJ, Wentzensen IM, Malhotra A, Clause A, Perry D, Moreno-De-Luca A, Bell M. Expanding the Phenotype of TUBB2A-Related Tubulinopathy: Three Cases of a Novel, Heterozygous TUBB2A Pathogenic Variant p.Gly98Arg. Mol Syndromol. 2021 Mar;12(1):33-40. doi: 10.1159/000512160. Epub 2020 Dec 9.